Clinical Trial Update: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]

View source ↗

Summary

Regeneron's bbT369 Phase 1 study in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a form of B-cell non-Hodgkin's lymphoma, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• bbT369

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Status: TERMINATED